FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Pharm Exec14d
FDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control ...
Medscape14d
FDA Okays New Rapid-Acting Biosimilar Insulin for Diabetes
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
BioSpace14d
Sanofi Challenges Novo With First FDA Nod for NovoLog Biosimilar
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market.
Medical Xpress12d
FDA approves first rapid-acting insulin biosimilar for patients with diabetes
The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj ... "The FDA has now ...
Two local counties, others sue over price of insulin
Two counties in the Charlotte area have filed lawsuits in the last few weeks over the price of insulin. Gaston County and ...
Medscape12d
Despite Price Caps, Some Still Struggle to Access Insulin
While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...
pharmaphorum13d
First biosimilar fast-acting insulin reaches US market
The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...
Pharmabiz15d
US FDA approves Sanofi-Aventis’ rapid-acting insulin biosimilar product Merilog for improvement of glycaemic control in patients with diabetes
Aventis’ rapid-acting insulin biosimilar product Merilog for improvement of glycaemic control in patients with diabetes: Maryland Monday, February 17, 202 ...